News & Updates
Filter by Specialty:
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
27 Nov 2023
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
24 Nov 2023
Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
Chinese patients with pancreatic cancer have a lower incidence of thromboembolism compared with Western populations, and thromboembolism does not affect overall survival (OS), researchers from the Chinese University of Hong Kong (CUHK) have reported.
Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
22 Nov 2023
Melanoma diagnoses in 2020 tend to have thicker, more advanced tumours
Diagnoses of invasive cutaneous melanoma in the year 2020 are characterized by thicker, more ulcerated, and more advanced tumours, a recent study has found. Of note, a 2020 diagnosis is not associated with survival.
